0000878526-19-000054.txt : 20190402 0000878526-19-000054.hdr.sgml : 20190402 20190402163347 ACCESSION NUMBER: 0000878526-19-000054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20190401 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190402 DATE AS OF CHANGE: 20190402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATUS MEDICAL INC CENTRAL INDEX KEY: 0000878526 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770154833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33001 FILM NUMBER: 19725437 BUSINESS ADDRESS: STREET 1: 6701 KOLL CENTER PARKWAY, SUITE 120 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252236700 MAIL ADDRESS: STREET 1: 6701 KOLL CENTER PARKWAY, SUITE 120 CITY: PLEASANTON STATE: CA ZIP: 94566 8-K 1 a2019-04x028xksaleofmedixb.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 1, 2019
 
 Natus Medical Incorporated
(Exact name of registrant as specified in its charter)
 
000-33001
(Commission File Number)
 
 
 
 
Delaware
 
77-0154833
(State or other jurisdiction
of Incorporation)
 
(I.R.S. Employer
Identification No.)
6701 Koll Center Parkway, Suite 120
Pleasanton, CA 94566
(Address of principal executive offices)
925-223-6700
(Registrant’s telephone number, including area code) (Zip Code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         o

 









Item 7.01.
Regulation FD Disclosure
On April 2, 2019, Natus Medical Incorporated, a Delaware corporation (“Natus” or the “Company”) issued a press release (the “Press Release”) announcing that it has signed an agreement to sell its wholly-owned subsidiary, Medix Medical Devices, SRL (“Medix”) in an employee led buyout. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Current Report on Form 8-K pursuant to Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01.
Financial Statements and Exhibits
(d) Exhibits.
 
Exhibit No.
  
Description
99.1
  
Press release dated April 2, 2019.

 


 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NATUS MEDICAL INCORPORATED
 
 
 
 
Date: April 2, 2019
 
 
 
By:
 
/s/ B. Drew Davies
 
 
 
 
 
 
B. Drew Davies
 
 
 
 
 
 
Executive Vice President & Chief Financial Officer






Exhibit Index
 
Exhibit No.
  
Description
  


EX-99.1 2 a2019-04x02saleofmedixbusi.htm EXHIBIT 99.1 Exhibit


natusa73.jpg


Natus Announces Sale of Medix Business

“Local Management to acquire the stock of Natus' Argentinian subsidiary”

PLEASANTON, Calif. (April 2, 2019) - Natus Medical Incorporated (NASDAQ:BABY) (the “Company” or “Natus”), a leading provider of medical devices and services, today announced that it has signed a definitive agreement to sell its wholly-owned subsidiary, Medix Medical Devices, SRL (“Medix”), in an employee led buyout.

As part of this divestiture, Natus will sell the Medix line of products, including incubators, warmers and other Medix products. Under its new ownership, Medix will continue to distribute Medix products as well as the previously distributed line of Natus products and other third party products in Argentina and Venezuela. Medix will also provide ongoing customer service, sales and customer support, and warranty and repair services for the Medix line of products.

“This divestiture is an important step toward refocusing our business on our core products and investing in the markets we expect to grow in the future,” said Jonathan A. Kennedy, President and Chief Executive Officer of Natus. “We remain committed to the markets we serve, and will ensure a smooth and orderly transition for our customers and employees.”

Expected Financial Impact of the Divestiture

The Medix business generated $7.6 million of revenue in 2018 and was expected to contribute approximately $6.0 million to 2019 revenue. The divestiture of Medix is expected to be accretive to Natus’ operating income margin going forward. We anticipate incurring $3.0 million to $4.0 million of transaction and disposal expenses as part of the divestiture. We will update full year revenue guidance with the impact of this divestiture in our Q1 2019 earnings release.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. These forward-looking statements include, without limitation, statements regarding creating a more efficient operating model, creating a stronger and more profitable company, enhancing focus on operational excellence, positioning the company for growth and driving long-term value for stakeholders. These statements relate to current estimates and assumptions of our management as of the date of this press release and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. The Company's future results could differ materially due to a number of factors, including the ability of the Company to realize the anticipated benefits from the new





structure or from its consolidation strategy, effects of competition, the Company's ability to successfully integrate and achieve its profitability goals from recent acquisitions, the demand for Natus products and services, the impact of adverse global economic conditions and changing governmental regulations, including foreign exchange rate changes, on the Company's target markets, the Company's ability to expand its sales in international markets, the Company's ability to maintain current sales levels in a mature domestic market, the Company's ability to control costs, risks associated with bringing new products to market, and the Company's ability to fulfill product orders on a timely basis, as well as those factors identified under the heading Item 1A “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Natus disclaims any obligation to update information contained in any forward looking statement, except as required by law.

About Natus Medical Incorporated

Natus is a leading provider of medical devices and services used for the screening, treatment and monitoring of common medical conditions in newborn care, hearing, balance impairment, neurological dysfunction, neurosurgery and sleep disorders.

Additional information about Natus Medical Incorporated can be found at www.natus.com.


CONTACTS:
Natus Medical Incorporated
Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com    


GRAPHIC 3 natusa73.jpg begin 644 natusa73.jpg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end